The FDA has proposed cutting fees for early-stage companies conducting clinical development in the U.S. instead of abroad. The proposal is designed to incentivize U.S. drug development by tacking on ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback